Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

immersive

Virtual Patient Engagement Program: A Customer Story

Our client wanted to better understand the needs, preferences, and treatment gaps among adult patients with a rare genetic disease...

Impetus Digital

Origins Insights Offering Explained

Origins believe that the patient voice not only should but must be included at all stages of the product lifecycle, we believe the question is no longer about why, but...

Origins – The Patient Focused Specialists

Introduction to Origins

In this short video Mark Corbett, Chief Innovation Officer at Resonant Group, gives a brief introduction to Origins, the patient focused specialist agency.If you'd like to know more, visit the...

Origins – The Patient Focused Specialists

Origins’ Strategy Offering Explained

What do we mean when we say that at Origins, we provide patient focused strategies throughout the product lifecycle? In this short video Origins’ Director Su Smith explains our strategy...

Origins – The Patient Focused Specialists

- PMLiVE

bluebird bio sells second FDA priority review voucher for $95m

The company sold its first voucher to Dutch biotech Argenx for $102m

- PMLiVE

FDA approves Ferring’s Adstiladrin as first gene therapy for bladder cancer

Non-muscle-invasive bladder cancer represents around 75% of all new bladder cancer cases

- PMLiVE

Roche’s COVID-19 antibody receives FDA approval for hospitalised adults

The decision makes Actemra the first FDA-approved monoclonal antibody to treat COVID-19

- PMLiVE

FDA lifts partial clinical hold on bluebird bio’s sickle cell gene therapy studies

The company can now resume the enrolment and treatment of patients aged two to 17 years

- PMLiVE

FDA approves updated COVID-19 boosters for children aged from six months

The Moderna and Pfizer/BioNTech boosters both target the BA.4/BA.5 omicron subvariants

- PMLiVE

Pfizer’s RSV vaccine candidate accepted for FDA priority review for use in older adults

A phase 3 study showed the vaccine was 85.7% effective in those with three or more symptoms

- PMLiVE

ORIGINS cements its specialist position with a truly patient focused offering

Origins are the patient focused specialists that create and deliver strategy, insights, experience data and solutions across the product lifecycle

Origins – The Patient Focused Specialists

- PMLiVE

Pfizer/BioNTech submit FDA application for BA.4/BA.5 COVID-19 vaccine in children under five

The vaccine is already authorised as a booster for ages five years and older in the US and EU

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links